Effectiveness of Neoadjuvant Trastuzumab and Chemotherapy in HER2-overexpressing Breast Cancer

Journal of Cancer Research and Clinical Oncology - Germany
doi 10.1007/s00432-013-1436-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

New England Journal of Medicine
Medicine
2012English

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine
Medicine
2005English

Trastuzumab-Dm1: A Review of the Novel Immuno-Conjugate for HER2- Overexpressing Breast Cancer

The Open Breast Cancer Journal
2009English

Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

T-Bet Expression in Intratumoral Lymphoid Structures After Neoadjuvant Trastuzumab Plus Docetaxel for HER2-overexpressing Breast Carcinoma Predicts Survival

British Journal of Cancer
Cancer ResearchOncology
2011English

Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells With Primary Trastuzumab Resistance

Anti-Cancer Agents in Medicinal Chemistry
Cancer ResearchMolecular MedicinePharmacology
2012English

Neoadjuvant Chemotherapy in Breast Cancer

English

Cost-Effectiveness Analysis of Neoadjuvant Chemotherapy With Zoledronic Acid for HER2-Negative Breast Cancer in Japan: The JONIE1 Study

Health
2019English

Prolonged Survival of Patients Receiving Trastuzumab Beyond Disease Progression for HER2 Overexpressing Metastatic Breast Cancer (MBC)

Oncology Research and Treatment
Cancer ResearchOncologyHematology
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy